ReviewClinical reviews in allergy & immunology2023
The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.
Review in Clinical reviews in allergy & immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Pooled it
- Bidirectional association between rheumatoid arthritis and chronic obstructive pulmonary disease: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Probiotics in asthma: immunoregulatory mechanisms and emerging opportunities for respiratory delivery-a narrative review.Translational pediatrics · 2026Review
- Pediatric cystic fibrosis is associated with type 3 immune response.Molecular biology reports · 2026Article
- Pulmonary mucoidMicrobiology spectrum · 2026Article
- Deciphering the inhibitory mechanisms of Interleukin-17A through dynamic molecular insights: a path toward novel anti-inflammatory therapies.Molecular diversity · 2026Article
- IL-17A activates the PI3K/AKT/mTOR pathway to regulate bronchial fibroblast autophagy-mediated airway remodeling: evidence from conditional IL-17RA-deficient mice.Frontiers in physiology · 2026Article
- The lung microbiome and asthma: from inflammatory phenotype differentiation to microbe-based immunomodulatory strategies.Frontiers in immunology · 2026Review
- Porphyromonas gingivalis-induced glucose intolerance during periapical lesions requires its LPS throught a Th17 immune response.International journal of oral science · 2025Article
- Liujunzi Decoction Regulated Intestinal Flora Homeostasis to Relieve Lung-Gut Axis Inflammation in Asthma Flora Disorder Mice: Possibly Related to GATA3/ILC2.Chinese journal of integrative medicine · 2025Article
- The Lung Microbiome and Its Impact on Obstructive Sleep Apnea: A Diagnostic Frontier.Diagnostics (Basel, Switzerland) · 2025Review
- Neutrophilic inflammation in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.Frontiers in immunology · 2025Review
- Activation of Myeloid Dendritic Cells by Up-Regulating RAGE/JAK/STAT Pathway Induced by Cigarette Smoke Exposure in Mice With Emphysema.Mediators of inflammation · 2025Article
- Emerging role of the TCA cycle and its metabolites in lung disease.Frontiers in physiology · 2025Review
- Dual signaling cascade regulating gut-lung axis in Interleukin-6/Interleukin-17 for NSCLC immuno pathogenesis.Frontiers in immunology · 2025Review
- Biological mechanisms of pulmonary inflammation and its association with seropositive rheumatoid arthritis.Frontiers in immunology · 2025Review
- Respiratory microbiota, host immunity, respiratory viral infections and malignant tumors.Frontiers in microbiology · 2025Review
- Silencing SMAD4 inhibits inflammation and ferroptosis in asthma by blocking the IL-17A signaling pathway.Respiratory research · 2024Article
- Respiratory Diseases Associated With Organic Dust Exposure.The journal of allergy and clinical immunology. In practice · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The respiratory tract is home to a diverse microbial community whose influence on local and systemic immune responses is only beginning to be appreciated. Increasing reports have linked changes in this microbiome to a range of pulmonary and extrapulmonary disorders, including asthma, chronic obstructive pulmonary disease and rheumatoid arthritis. Central to many of these findings is the role of IL-17-type immunity as an important driver of inflammation. Despite the crucial role played by IL-17-mediated immune responses in protection against infection, overt Th17 cell responses have been implicated in the pathogenesis of several chronic inflammatory diseases. However, our knowledge of the influence of bacteria that commonly colonise the respiratory tract on IL-17-driven inflammatory responses remains sparse. In this article, we review the current knowledge on the role of specific members of the airway microbiota in the modulation of IL-17-type immunity and discuss how this line of research may support the testing of susceptible individuals and targeting of inflammation at its earliest stages in the hope of preventing the development of chronic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.